Connie Matsui
Connie Matsui's purchase track record
Connie Matsui has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/15/2025 | STRO | $40K | +62.3% | +281.7% | +5.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review. Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.
Transaction History
| STRO | ▲ Buy | Open Market | 50,000 | $40K | 10/15/2025 | View on chart |
| HALO | ▼ Sell | Gift | 10,470 | $0 | 11/29/2024 | View on chart |
| HALO | ▲ Buy | Grant | 6,501 | $0 | 4/25/2024 | View on chart |
| HALO | ▲ Buy | Grant | 8,065 | $0 | 5/5/2023 | View on chart |
| HALO | ▼ Sell | Gift | 9,250 | $0 | 11/16/2022 | View on chart |
| HALO | ▲ Buy | Grant | 6,206 | $0 | 5/5/2022 | View on chart |
| HALO | ▼ Sell | Open Market | 19,452 | $781K | 11/5/2021 | View on chart |
| HALO | ▼ Sell | Open Market | 12,548 | $512K | 11/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Sutro Biopharma Names New Business Development SVP
Sutro Biopharma has appointed Lucas Donigian as Senior Vice President of Business Development. This leadership addition is relevant for investors tracking the company's commercial strategy and partnership efforts. The move provides context for the stock's current trading levels and analyst expectations.
Sutro Biopharma Names New Business Development SVP. Sutro Biopharma has appointed Lucas Donigian as Senior Vice President of Business Development. This leadership addition is relevant for investors tracking the company's commercial strategy and partnership efforts. The move provides context for the stock's current trading levels and analyst expectations.